Tags

Type your tag names separated by a space and hit enter

Interleukin-31 and interleukin-31 receptor: New therapeutic targets for atopic dermatitis.
Exp Dermatol 2018; 27(4):327-331ED

Abstract

Atopic dermatitis (AD) is characterized by chronic, eczematous, severe pruritic skin lesions caused by skin barrier dysfunction and T helper (Th)2 cell-mediated immunity. Interleukin (IL)-31 is a potent pruritogenic cytokine primarily produced by Th2 cells. Both IL-31 transgenic mice and wild-type mice treated with IL-31 exhibit AD-like skin lesions and scratching behaviour. IL-31 receptor α-chain (IL-31RA) is also expressed in peripheral nerves and epidermal keratinocytes, and the roles of IL-31 on pruritus and skin barrier have been investigated. Recently, an anti-IL-31 receptor antibody was shown to significantly improve pruritus in AD patients. This review focuses on IL-31 and IL-31RA in AD.

Authors+Show Affiliations

Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan. Translational Research Department for Skin and Brain Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan.Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan. Singapore Immunology Network (SIgN), Institute of Medical Biology, Agency for Science, Technology and Research (A*STAR), Biopolis, Singapore City, Singapore.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

29524262

Citation

Nakashima, Chisa, et al. "Interleukin-31 and Interleukin-31 Receptor: New Therapeutic Targets for Atopic Dermatitis." Experimental Dermatology, vol. 27, no. 4, 2018, pp. 327-331.
Nakashima C, Otsuka A, Kabashima K. Interleukin-31 and interleukin-31 receptor: New therapeutic targets for atopic dermatitis. Exp Dermatol. 2018;27(4):327-331.
Nakashima, C., Otsuka, A., & Kabashima, K. (2018). Interleukin-31 and interleukin-31 receptor: New therapeutic targets for atopic dermatitis. Experimental Dermatology, 27(4), pp. 327-331. doi:10.1111/exd.13533.
Nakashima C, Otsuka A, Kabashima K. Interleukin-31 and Interleukin-31 Receptor: New Therapeutic Targets for Atopic Dermatitis. Exp Dermatol. 2018;27(4):327-331. PubMed PMID: 29524262.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Interleukin-31 and interleukin-31 receptor: New therapeutic targets for atopic dermatitis. AU - Nakashima,Chisa, AU - Otsuka,Atsushi, AU - Kabashima,Kenji, PY - 2018/03/01/accepted PY - 2018/3/11/pubmed PY - 2019/4/16/medline PY - 2018/3/11/entrez KW - IL-31 KW - Nemolizumab KW - atopic dermatitis SP - 327 EP - 331 JF - Experimental dermatology JO - Exp. Dermatol. VL - 27 IS - 4 N2 - Atopic dermatitis (AD) is characterized by chronic, eczematous, severe pruritic skin lesions caused by skin barrier dysfunction and T helper (Th)2 cell-mediated immunity. Interleukin (IL)-31 is a potent pruritogenic cytokine primarily produced by Th2 cells. Both IL-31 transgenic mice and wild-type mice treated with IL-31 exhibit AD-like skin lesions and scratching behaviour. IL-31 receptor α-chain (IL-31RA) is also expressed in peripheral nerves and epidermal keratinocytes, and the roles of IL-31 on pruritus and skin barrier have been investigated. Recently, an anti-IL-31 receptor antibody was shown to significantly improve pruritus in AD patients. This review focuses on IL-31 and IL-31RA in AD. SN - 1600-0625 UR - https://www.unboundmedicine.com/medline/citation/29524262/Interleukin_31_and_interleukin_31_receptor:_New_therapeutic_targets_for_atopic_dermatitis_ L2 - https://doi.org/10.1111/exd.13533 DB - PRIME DP - Unbound Medicine ER -